Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
DUBLIN, August 29, 2024--Prothena today announced that members of its senior management team will participate in two upcoming investor conferences in September 2024.
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.